$AUTL
Autolus Therapeutics plc Stock $autl

$autl Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000173046324000048 Filed on March 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q2
Revenue	$10.09M	$0.00	$0.00
YoY Change	681.04%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$18.18M	$15.73M	$11.12M
YoY Change	95.79%	112.2%	34.5%
% of Gross Profit
Research & Development	$30.67M	$25.16M	$36.74M
YoY Change	-2.15%	-21.84%	-3.85%
% of Gross Profit
Depreciation & Amortization	$1.806M	$1.775M	$1.512M
YoY Change	-4.9%	7.64%	-21.21%
% of Gross Profit
Operating Expenses	$30.67M	$40.89M	$47.86M
YoY Change	-24.51%	3.25%	2.98%
Operating Profit	-$38.76M		-$44.38M
YoY Change	-1.0%		13.6%
Interest Expense	$19.27M	-$24.52M	-$1.617M
YoY Change	-1420.7%	10513.85%	-6.04%
% of Operating Profit
Other Income/Expense, Net	-$13.94M	$594.0K	$482.0K
YoY Change	-1882.74%	-86.66%	-136.21%
Pretax Income	-$52.70M	-$64.81M	-$49.02M
YoY Change	20.37%	102.11%	-1.03%
Income Tax	-$8.000K	$12.36M	-$3.470M
% Of Pretax Income
Net Earnings	-$52.69M	-$77.17M	-$45.55M
YoY Change	32.35%	186.34%	8.31%
Net Earnings / Revenue	-522.15%
Basic Earnings Per Share	-$0.24		-$0.26
Diluted Earnings Per Share	-$0.24	-$0.44	-$0.26
COMMON SHARES
Basic Shares Outstanding	265.9M shares	174.0M shares	173.9M shares
Diluted Shares Outstanding	222.2M shares		173.9M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$758.5M	$239.6M	$307.5M
YoY Change	121.13%	-37.36%	42.07%
Cash & Equivalents	$758.5M	$239.6M	$307.5M
Short-Term Investments
Other Short-Term Assets	$13.80M	$11.19M	$47.87M
YoY Change	-13.86%	5414.29%	12.56%
Inventory
Prepaid Expenses	$11.13M	$8.638M
Receivables	$0.00	$109.0K	$100.0K
Other Receivables	$736.0K	$24.43M	$38.12M
Total Short-Term Assets	$804.3M	$275.3M	$355.4M
YoY Change	104.2%	-35.34%	37.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.41M	$34.86M	$91.11M
YoY Change	-45.69%	-0.99%	85.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.598M	$4.426M	$4.519M
YoY Change	0.88%	-27.25%	-24.27%
Total Long-Term Assets	$97.14M	$100.1M	$95.63M
YoY Change	46.99%	55.15%	73.82%
TOTAL ASSETS
Total Short-Term Assets	$804.3M	$275.3M	$355.4M
Total Long-Term Assets	$97.14M	$100.1M	$95.63M
Total Assets	$901.4M	$375.4M	$451.0M
YoY Change	95.98%	-23.43%	43.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.399M	$103.0K	$3.878M
YoY Change	296.32%	-80.6%	2293.83%
Accrued Expenses	$37.77M	$39.58M	$37.19M
YoY Change	-3.05%	-2.98%	5.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$43.99M	$44.74M	$41.06M
YoY Change	10.97%	-3.51%	15.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$409.0K	$357.0K	$180.6M
YoY Change	-99.73%	207.76%	182.45%
Total Long-Term Liabilities	$409.0K	$357.0K	$180.6M
YoY Change	-99.73%	207.76%	182.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.99M	$44.74M	$41.06M
Total Long-Term Liabilities	$409.0K	$357.0K	$180.6M
Total Liabilities	$319.4M	$263.9M	$221.7M
YoY Change	65.45%	37.74%	122.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$931.3M	-$878.6M	-$755.5M
YoY Change	31.17%	31.09%	25.83%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$582.0M	$111.5M	$229.3M
YoY Change
Total Liabilities & Shareholders Equity	$901.4M	$375.4M	$451.0M
YoY Change	95.98%	-23.43%	43.64%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q2
OPERATING ACTIVITIES
Net Income	-$52.69M	-$77.17M	-$45.55M
YoY Change	32.35%	186.34%	8.31%
Depreciation, Depletion And Amortization	$1.806M	$1.775M	$1.512M
YoY Change	-4.9%	7.64%	-21.21%
Cash From Operating Activities	-$40.51M	-$24.83M	-$38.15M
YoY Change	-4.49%	70.49%	23.82%
INVESTING ACTIVITIES
Capital Expenditures	$533.0K	$1.477M	$4.389M
YoY Change	-85.28%	133.33%	-266.25%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$533.0K	-$1.477M	-$4.389M
YoY Change	-85.28%	133.33%	66.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$561.4M	23.00K	-219.0K
YoY Change	-81350.51%	-99.99%
NET CHANGE
Cash From Operating Activities	-$40.51M	-24.83M	-38.15M
Cash From Investing Activities	-$533.0K	-1.477M	-4.389M
Cash From Financing Activities	$561.4M	23.00K	-219.0K
Net Change In Cash	$519.2M	-26.29M	-42.76M
YoY Change	-1211.04%	-112.62%	27.83%
FREE CASH FLOW
Cash From Operating Activities	-$40.51M	-$24.83M	-$38.15M
Capital Expenditures	$533.0K	$1.477M	$4.389M
Free Cash Flow	-$41.05M	-$26.31M	-$42.54M
YoY Change	-10.85%	73.1%	51.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001730463
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q4	autl	Deduction Of Royalties Payable DeductionOfRoyaltiesPayable	0.5
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38547
CY2023	dei	Entity Registrant Name EntityRegistrantName	Autolus Therapeutics plc
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	The Mediaworks
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	191 Wood Lane,
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	London,
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	W12 7FP
CY2023	dei	Entity Address Country EntityAddressCountry	GB
CY2023	dei	City Area Code CityAreaCode	(44) 20
CY2023	dei	Local Phone Number LocalPhoneNumber	3829 6230
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	true
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	279466250	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	265926305	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	1438
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Reading, United Kingdom
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239566000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382436000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	769000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	325000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34967000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43010000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	275302000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	425771000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34862000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35209000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	380000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2176000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	60791000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23210000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	983000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1832000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	3063000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2076000	usd
CY2023Q4	us-gaap	Assets Assets	375381000	usd
CY2022Q4	us-gaap	Assets Assets	490274000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	103000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	531000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39581000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40797000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5053000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5038000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44737000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46366000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47914000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19218000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	170899000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	125900000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	357000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	116000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	263907000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	191600000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1018902000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1007625000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-28992000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38898000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-878562000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-670179000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	111474000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	298674000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	375381000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	490274000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	130481000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	117354000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	110839000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	46745000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31899000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31865000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3791000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-515000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-676000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	382000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-179701000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-143408000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-141050000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2861000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2038000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-145000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	13505000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1708000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	262000	usd
CY2023	us-gaap	Interest Expense InterestExpense	45067000	usd
CY2022	us-gaap	Interest Expense InterestExpense	8905000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1105000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5159000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-988000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142038000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173941926	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94993400	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	210032000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	228161000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9937000	usd
CY2021	autl	Stock Vested During Period Value Restricted Stock StockVestedDuringPeriodValueRestrictedStock	0	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	127000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	9868000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2709000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-142096000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	313320000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	152390000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12014000	usd
CY2022	autl	Stock Vested During Period Value Restricted Stock StockVestedDuringPeriodValueRestrictedStock	0	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	117000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-30328000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148839000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	298674000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11250000	usd
CY2023	autl	Stock Vested During Period Value Restricted Stock StockVestedDuringPeriodValueRestrictedStock	0	usd
CY2023	autl	Stock Issued During Period Value Restricted Stock Award Forfeited Reversal StockIssuedDuringPeriodValueRestrictedStockAwardForfeitedReversal	0	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	9906000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-208383000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	111474000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-208383000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148839000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-142096000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6565000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7422000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8458000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3791000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-515000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-672000	usd
CY2023	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	11204000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	12014000	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	9937000	usd
CY2023	autl	Collaboration Agreement Non Cash Interest Expense And Cumulative Catch Up Adjustment CollaborationAgreementNonCashInterestExpenseAndCumulativeCatchUpAdjustment	44999000	usd
CY2022	autl	Collaboration Agreement Non Cash Interest Expense And Cumulative Catch Up Adjustment CollaborationAgreementNonCashInterestExpenseAndCumulativeCatchUpAdjustment	8884000	usd
CY2021	autl	Collaboration Agreement Non Cash Interest Expense And Cumulative Catch Up Adjustment CollaborationAgreementNonCashInterestExpenseAndCumulativeCatchUpAdjustment	1093000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	7604000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-3996000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	usd
CY2023	autl	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	4058000	usd
CY2022	autl	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	3432000	usd
CY2021	autl	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	3728000	usd
CY2023	autl	Gain Loss On Incentive And Reassessment GainLossOnIncentiveAndReassessment	0	usd
CY2022	autl	Gain Loss On Incentive And Reassessment GainLossOnIncentiveAndReassessment	0	usd
CY2021	autl	Gain Loss On Incentive And Reassessment GainLossOnIncentiveAndReassessment	-9000	usd
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-95000	usd
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	382000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2023	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	986000	usd
CY2022	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	268000	usd
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	72000	usd
CY2023	autl	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	-10695000	usd
CY2022	autl	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	10962000	usd
CY2021	autl	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	-5574000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1726000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-161000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-503000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-937000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-575000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-509000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	22000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1816000	usd
CY2023	autl	Increase Decrease In Accrued Liabilities Lease Liability And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities	998000	usd
CY2022	autl	Increase Decrease In Accrued Liabilities Lease Liability And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities	16007000	usd
CY2021	autl	Increase Decrease In Accrued Liabilities Lease Liability And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities	-2021000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-13555000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4687000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2405000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-145587000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-112308000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117861000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10986000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10841000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10986000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	245900000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	usd
CY2021	autl	Proceeds From Issuance Of Contract With Customer Liability ProceedsFromIssuanceOfContractWithCustomerLiability	-50000000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	910000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10361000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	11453000	usd
CY2023	autl	Payment Of Contract With Customer Liability Issuance Costs PaymentOfContractWithCustomerLiabilityIssuanceCosts	0	usd
CY2022	autl	Payment Of Contract With Customer Liability Issuance Costs PaymentOfContractWithCustomerLiabilityIssuanceCosts	0	usd
CY2021	autl	Payment Of Contract With Customer Liability Issuance Costs PaymentOfContractWithCustomerLiabilityIssuanceCosts	509000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-883000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	223610000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	284063000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15030000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-28376000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-754000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-142426000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72085000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	156591000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	382761000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310676000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154085000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	240335000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	382761000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310676000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	551000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	471000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	364000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	433000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2864000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3712000	usd
CY2023	autl	Right Of Use Assets Terminated And Obtained In Exchange For Operating Lease Liability Net RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet	3000	usd
CY2022	autl	Right Of Use Assets Terminated And Obtained In Exchange For Operating Lease Liability Net RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet	0	usd
CY2021	autl	Right Of Use Assets Terminated And Obtained In Exchange For Operating Lease Liability Net RightOfUseAssetsTerminatedAndObtainedInExchangeForOperatingLeaseLiabilityNet	28517000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	41148000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9785000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	627000	usd
CY2023	autl	Capitalized Sharebased Compensation CapitalizedSharebasedCompensation	46000	usd
CY2022	autl	Capitalized Sharebased Compensation CapitalizedSharebasedCompensation	-6000	usd
CY2021	autl	Capitalized Sharebased Compensation CapitalizedSharebasedCompensation	0	usd
CY2023	autl	Hosting Arrangement Service Contract Implementation Cost Capitalized After Accumulated Amortization Current And Noncurrent HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent	564000	usd
CY2022	autl	Hosting Arrangement Service Contract Implementation Cost Capitalized After Accumulated Amortization Current And Noncurrent HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent	230000	usd
CY2021	autl	Hosting Arrangement Service Contract Implementation Cost Capitalized After Accumulated Amortization Current And Noncurrent HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent	100000	usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	272000	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1103000	usd
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	245000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	9868000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239566000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382436000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	310338000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	769000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	325000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	338000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	240335000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	382761000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310676000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Nature of the Business<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autolus Therapeutics plc and its subsidiaries (collectively “Autolus” or the “Company”) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autolus Therapeutics plc is registered in England and Wales. Its registered office is The MediaWorks, 191 Wood Lane, London, W12 7FP, United Kingdom.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a public limited company incorporated under the laws of England and Wales, and qualifies as a “foreign private issuer,” as such term is defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”), and Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and, therefore, is not subject to the same requirements that are imposed upon U.S. domestic issuers by the Securities and Exchange Commission (the “SEC”). The Company has decided to voluntarily file periodic reports, such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K on U.S. domestic issuer forms, which are more detailed and extensive in certain respects, and which must be filed more promptly than the forms currently required for foreign private issuers. Although the Company has voluntarily chosen to file periodic reports and current reports on U.S. domestic issuer forms, the Company will maintain its status as a foreign private issuer and is not subject to certain other requirements imposed on U.S. domestic issuers including its officers, directors, and principal shareholders are not subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239600000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-208400000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-878600000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239600000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, share-based compensation including assessing the probability of meeting performance conditions, income taxes, initial fair value of warrants, and accrued interest expense on liability related to future royalties and sales milestones, net and related cumulative catch-up adjustment, initial lease term of the Company's new manufacturing facility (The Nucleus), and incremental borrowing rates related to the Company's leased properties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</span></div>
CY2021Q4	autl	Lessor Operating Lease Number Of Contracts LessorOperatingLeaseNumberOfContracts	2	contract
CY2021Q4	us-gaap	Proceeds From Deposits From Customers ProceedsFromDepositsFromCustomers	100000	usd
CY2021Q4	us-gaap	Proceeds From Deposits From Customers ProceedsFromDepositsFromCustomers	100000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	117354000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-143408000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	272000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.57
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	110839000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-141050000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents and restricted cash. The Company places cash and cash equivalents and restricted cash with established financial institutions with strong credit ratings. The Company holds significant amounts of cash and cash equivalents that are in excess of federally insured limits in various currencies, placed with one or more financial institutions for varying periods according to expected liquidity requirements. The Company's cash and cash equivalents are held with multiple banks and financial institutions. Management monitors the credit rating of those banks and financial institutions on a regular basis. The Company has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.</span></div>
CY2022	autl	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	impairment of long-lived asset
CY2023	autl	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	impairment of long-lived asset
CY2021	autl	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	impairment of long-lived asset
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	400000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.97
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.97
CY2023	autl	Research And Development Income Tax Credits ResearchAndDevelopmentIncomeTaxCredits	19500000	usd
CY2022	autl	Research And Development Income Tax Credits ResearchAndDevelopmentIncomeTaxCredits	24600000	usd
CY2021	autl	Research And Development Income Tax Credits ResearchAndDevelopmentIncomeTaxCredits	24000000.0	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2600000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1800000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2300000	usd
CY2023Q4	autl	Number Of Distinct Performance Obligations NumberOfDistinctPerformanceObligations	1	performanceobligation
CY2023Q4	autl	Number Of Distinct Performance Obligations NumberOfDistinctPerformanceObligations	1	performanceobligation
CY2023	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	19892000	usd
CY2022	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	8005000	usd
CY2021	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	1093000	usd
CY2023	autl	Collaboration Agreement Cumulative Catch Up Adjustment CollaborationAgreementCumulativeCatchUpAdjustment	-25107000	usd
CY2022	autl	Collaboration Agreement Cumulative Catch Up Adjustment CollaborationAgreementCumulativeCatchUpAdjustment	-879000	usd
CY2021	autl	Collaboration Agreement Cumulative Catch Up Adjustment CollaborationAgreementCumulativeCatchUpAdjustment	0	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	68000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	21000	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	12000	usd
CY2023	us-gaap	Interest Expense InterestExpense	45067000	usd
CY2022	us-gaap	Interest Expense InterestExpense	8905000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1105000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	184635000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	28593000	usd
CY2023Q4	autl	Research And Development Claims Receivable Current ResearchAndDevelopmentClaimsReceivableCurrent	19209000	usd
CY2022Q4	autl	Research And Development Claims Receivable Current ResearchAndDevelopmentClaimsReceivableCurrent	24685000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8638000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12337000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2771000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2701000	usd
CY2023Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	1787000	usd
CY2022Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	1494000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1515000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1435000	usd
CY2023Q4	autl	Lease And Lease Deposit Receivable Current LeaseAndLeaseDepositReceivableCurrent	938000	usd
CY2022Q4	autl	Lease And Lease Deposit Receivable Current LeaseAndLeaseDepositReceivableCurrent	32000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	109000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	121000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	0	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	203000	usd
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	34967000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43010000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	28774000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25647000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34862000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35209000	usd
CY2023	us-gaap	Depreciation Depreciation	6600000	usd
CY2022	us-gaap	Depreciation Depreciation	7300000	usd
CY2021	us-gaap	Depreciation Depreciation	8600000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	65000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	90000	usd
CY2023Q4	autl	Accrued Research And Development Cost Current AccruedResearchAndDevelopmentCostCurrent	19825000	usd
CY2022Q4	autl	Accrued Research And Development Cost Current AccruedResearchAndDevelopmentCostCurrent	26478000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14757000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10181000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4466000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3745000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	533000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	393000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39581000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40797000	usd
CY2022Q4	autl	Number Of Development Payments NumberOfDevelopmentPayments	2	payment
CY2021Q4	autl	Debt Financing Commitment Maximum Amount To Be Received DebtFinancingCommitmentMaximumAmountToBeReceived	150000000	usd
CY2023Q4	autl	Units Of Accounting UnitsOfAccounting	3	unit
CY2023Q4	autl	Units Of Accounting UnitsOfAccounting	3	unit
CY2023Q4	autl	Units Of Accounting UnitsOfAccounting	3	unit
CY2023Q4	autl	Units Of Accounting UnitsOfAccounting	3	unit
CY2022Q4	autl	Number Of Development Payments NumberOfDevelopmentPayments	2	payment
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.35
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	10000000.0	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023	autl	Warrants Or Rights Outstanding Fair Value Assumptions Risk Free Interest Rate WarrantsOrRightsOutstandingFairValueAssumptionsRiskFreeInterestRate	0.0104
CY2023	autl	Warrants Or Rights Outstanding Fair Value Assumptions Expected Volatility Rate WarrantsOrRightsOutstandingFairValueAssumptionsExpectedVolatilityRate	0.8023
CY2023	autl	Warrant Or Right Outstanding Fair Value Assumption Expected Dividend Rate WarrantOrRightOutstandingFairValueAssumptionExpectedDividendRate	0
CY2018Q2	autl	Equity Conversion Ratio EquityConversionRatio	3.185
CY2020Q3	autl	Sale Of Stock Authorized Amount SaleOfStockAuthorizedAmount	100000000	usd
CY2020Q3	autl	Commission Percentage Of Gross Sales Price CommissionPercentageOfGrossSalesPrice	0.030
CY2022	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	29600000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10310800	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.90
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	96000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8783330	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.29
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10107	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.69
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	487607	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.10
CY2023	autl	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue	1203000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	640031	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	13.60
CY2023	autl	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodIntrinsicValue	90000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17956385	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	48968000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6318107	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.48
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y11M12D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	7601000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	17956385	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	48968000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10000.00	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1200000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11400000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11100000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	13000000.0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11250000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12014000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9937000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-208383000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-148839000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-142096000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-208383000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-208383000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-148839000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-148839000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-142096000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-142096000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173941926	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173941926	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	94993400	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94993400	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72084078	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72084078	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.20
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.57
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.57
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.97
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.97
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21338127	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13979437	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12127411	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	313971	shares
CY2020Q4	autl	Accrued License Fees Current AccruedLicenseFeesCurrent	350000	gbp
CY2023Q4	autl	Accrued License Fees Current AccruedLicenseFeesCurrent	180000	gbp
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-209766000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-149455000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-142736000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-208402000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-148567000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142038000	usd
CY2023	autl	Current Foreign Federal Tax Expense Benefit CurrentForeignFederalTaxExpenseBenefit	859000	usd
CY2022	autl	Current Foreign Federal Tax Expense Benefit CurrentForeignFederalTaxExpenseBenefit	440000	usd
CY2021	autl	Current Foreign Federal Tax Expense Benefit CurrentForeignFederalTaxExpenseBenefit	148000	usd
CY2023	autl	Current Foreign State And Local Tax Expense Benefit CurrentForeignStateAndLocalTaxExpenseBenefit	5000	usd
CY2022	autl	Current Foreign State And Local Tax Expense Benefit CurrentForeignStateAndLocalTaxExpenseBenefit	19000	usd
CY2021	autl	Current Foreign State And Local Tax Expense Benefit CurrentForeignStateAndLocalTaxExpenseBenefit	19000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	104000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	26000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	968000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	485000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	168000	usd
CY2023	autl	Deferred Foreign Federal Income Tax Expense Benefit DeferredForeignFederalIncomeTaxExpenseBenefit	-1002000	usd
CY2022	autl	Deferred Foreign Federal Income Tax Expense Benefit DeferredForeignFederalIncomeTaxExpenseBenefit	-218000	usd
CY2021	autl	Deferred Foreign Federal Income Tax Expense Benefit DeferredForeignFederalIncomeTaxExpenseBenefit	-162000	usd
CY2023	autl	Deferred Foreign State And Local Income Tax Expense Benefit DeferredForeignStateAndLocalIncomeTaxExpenseBenefit	15000	usd
CY2022	autl	Deferred Foreign State And Local Income Tax Expense Benefit DeferredForeignStateAndLocalIncomeTaxExpenseBenefit	5000	usd
CY2021	autl	Deferred Foreign State And Local Income Tax Expense Benefit DeferredForeignStateAndLocalIncomeTaxExpenseBenefit	52000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-987000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-213000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-110000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	272000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19500	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-208402000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-148567000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142038000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.235
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-48974000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-28228000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-26987000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4589000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4681000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	4595000	usd
CY2023	autl	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Depreciation And Amortization Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingDepreciationAndAmortizationAmount	31268000	usd
CY2022	autl	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Depreciation And Amortization Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingDepreciationAndAmortizationAmount	16900000	usd
CY2021	autl	Effective Income Tax Rate Reconciliation Nondeductible Expense Excluding Depreciation And Amortization Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcludingDepreciationAndAmortizationAmount	13984000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	96000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	10000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	167000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	21245000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15670000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15745000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	961000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	583000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1727000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-26000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	18000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	17000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	272000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	58000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	968000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	485000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	168000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-987000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-213000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-110000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14834000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13576000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	104534000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	80203000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	6653000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	4252000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	126021000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	98031000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	122958000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	95955000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	3063000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2076000	usd
CY2023	autl	Increase Decrease In Deferred Tax Assets Gross IncreaseDecreaseInDeferredTaxAssetsGross	-1000000.0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	3100000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	418100000	usd
CY2023Q4	autl	Number Of Manufacturing Suites With Extended Lease Term NumberOfManufacturingSuitesWithExtendedLeaseTerm	1	manufacturingsuite
CY2022	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	7500000	usd
CY2023Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	200000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	60791000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23210000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5053000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5038000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47914000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19218000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52967000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24256000	usd
CY2023	us-gaap	Lease Cost LeaseCost	9264000	usd
CY2022	us-gaap	Lease Cost LeaseCost	5887000	usd
CY2021	us-gaap	Lease Cost LeaseCost	7475000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	10407000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4575000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P16Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0744
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0677
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7937000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6899000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6667000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6524000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5803000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	57038000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	90868000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	37901000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52967000	usd
CY2021Q4	autl	Lessor Operating Lease Number Of Contracts LessorOperatingLeaseNumberOfContracts	2	contract
CY2021Q4	autl	Lessor Operating Lease Number Of Third Parties LessorOperatingLeaseNumberOfThirdParties	2	thirdparty
CY2021Q4	autl	Lessor Operating Lease Number Of Manufacturing Properties LessorOperatingLeaseNumberOfManufacturingProperties	2	contract
CY2021Q4	us-gaap	Proceeds From Deposits From Customers ProceedsFromDepositsFromCustomers	127000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	241000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	240000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	49000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	241000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	240000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	49000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	261000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	261000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	203000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	123000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	106000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	954000	usd
CY2023	autl	Long Term Supply Agreement Period LongTermSupplyAgreementPeriod	P10Y
CY2023Q4	autl	Number Of Options To Renew Agreement NumberOfOptionsToRenewAgreement	2	renewaloption
CY2023	autl	Long Term Supply Agreement Renewal Period LongTermSupplyAgreementRenewalPeriod	P5Y
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	2000000.0	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1700000	usd
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	1600000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	95653000	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	58419000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	400000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021Q1	us-gaap	Severance Costs1 SeveranceCosts1	1200000	usd
CY2021Q4	autl	Number Of Directors NumberOfDirectors	1	director
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	56500000	shares
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	113000000.0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	343027000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	268558000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	328000	usd
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	334000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	50530000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	40571000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	393885000	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	309463000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34667000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31017000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	465000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2119000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26861000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17366000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1821000	usd
CY2022Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1983000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2272000	usd
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2000000	usd
CY2023Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	0	usd
CY2022Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	46000	usd
CY2023Q1	us-gaap	Assets Assets	459971000	usd
CY2022Q1	us-gaap	Assets Assets	363994000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	353000	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	153000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34463000	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24513000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4821000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4174000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	39637000	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	28840000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22495000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15081000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	130805000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	48806000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	114000	usd
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	124000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	193051000	usd
CY2022Q1	us-gaap	Liabilities Liabilities	92851000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1010041000	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	845448000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33257000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16025000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-709990000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-558402000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	266920000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	271143000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	459971000	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	363994000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	307500000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	216437000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	332000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	325000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	47533000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42198000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	355365000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	258960000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	52443000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36857000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33794000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	295000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1888000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	54251000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15230000	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1864000	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1835000	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2360000	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2244000	usd
CY2023Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	0	usd
CY2022Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	25000	usd
CY2023Q2	us-gaap	Assets Assets	450992000	usd
CY2022Q2	us-gaap	Assets Assets	313976000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3878000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	162000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30954000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31360000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6231000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3995000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	41063000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	35517000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44707000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13208000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	135764000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	50615000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	122000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	115000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	221656000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	99455000	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1012709000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	848370000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27957000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33510000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-755542000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-600461000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	229336000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	214521000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	450992000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	313976000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	256415000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163053000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	434000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	315000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	51533000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	48943000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	308382000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	212311000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34637000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32474000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	136000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1718000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	59403000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13235000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	943000	usd
CY2022Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1688000	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2597000	usd
CY2022Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2396000	usd
CY2023Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	0	usd
CY2022Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	8000	usd
CY2023Q3	us-gaap	Assets Assets	406098000	usd
CY2022Q3	us-gaap	Assets Assets	263830000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	661000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	334000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31388000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34669000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5491000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3815000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	37540000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	38818000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	46967000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11310000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	140778000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	295000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	105000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	225580000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	102676000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1015577000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	851824000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33794000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-47564000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-801391000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-643228000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	180518000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	161154000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	406098000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	263830000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27388000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28365000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9284000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7987000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3768000	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-39148000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-36186000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	782000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	860000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3446000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	28000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	4905000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	1790000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-677000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-902000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39825000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37088000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-26000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-39811000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-37062000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5641000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-7455000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34170000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44517000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173825825	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173825825	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90914175	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90914175	shares
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33232000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30794000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11122000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8269000	usd
CY2023Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-23000	usd
CY2022Q2	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-44377000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-39063000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	482000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1331000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3403000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	89000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	5020000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	1810000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1135000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3052000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45512000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42115000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-56000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-45552000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-42059000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5300000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-17485000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40252000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59544000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173860491	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173860491	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90931964	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90931964	shares
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32318000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31485000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10611000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8231000	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-382000	usd
CY2022Q3	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42905000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-37347000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1597000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3740000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	3646000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	165000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	5014000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1850000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2965000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5425000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45870000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42772000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-45849000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-42767000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5837000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-14054000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51686000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56821000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173984101	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173984101	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91240801	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91240801	shares

Files In Submission

Name	View Source	Status
0001730463-24-000048-index-headers.html	Edgar Link	pending
0001730463-24-000048-index.html	Edgar Link	pending
0001730463-24-000048.txt	Edgar Link	pending
0001730463-24-000048-xbrl.zip	Edgar Link	pending
autl-20231231.htm	Edgar Link	pending
autl-20231231.xsd	Edgar Link	pending
autl-20231231_cal.xml	Edgar Link	unprocessable
autl-20231231_g1.jpg	Edgar Link	pending
autl-20231231_g2.jpg	Edgar Link	pending
autl-20231231_g3.jpg	Edgar Link	pending
autl-20231231_g4.jpg	Edgar Link	pending
exhibit1012biontech.htm	Edgar Link	pending
exhibit1012biontech001.jpg	Edgar Link	pending
exhibit1012biontech002.jpg	Edgar Link	pending
exhibit1012biontech003.jpg	Edgar Link	pending
exhibit1012biontech004.jpg	Edgar Link	pending
exhibit1012biontech005.jpg	Edgar Link	pending
exhibit1012biontech006.jpg	Edgar Link	pending
exhibit1012biontech007.jpg	Edgar Link	pending
exhibit1012biontech008.jpg	Edgar Link	pending
exhibit1012biontech009.jpg	Edgar Link	pending
exhibit1012biontech010.jpg	Edgar Link	pending
exhibit1012biontech011.jpg	Edgar Link	pending
exhibit1012biontech012.jpg	Edgar Link	pending
exhibit1012biontech013.jpg	Edgar Link	pending
exhibit1012biontech014.jpg	Edgar Link	pending
exhibit1012biontech015.jpg	Edgar Link	pending
exhibit1012biontech016.jpg	Edgar Link	pending
exhibit1012biontech017.jpg	Edgar Link	pending
exhibit1012biontech018.jpg	Edgar Link	pending
exhibit1012biontech019.jpg	Edgar Link	pending
exhibit1012biontech020.jpg	Edgar Link	pending
exhibit1012biontech021.jpg	Edgar Link	pending
exhibit1012biontech022.jpg	Edgar Link	pending
exhibit1012biontech023.jpg	Edgar Link	pending
exhibit1012biontech024.jpg	Edgar Link	pending
exhibit1012biontech025.jpg	Edgar Link	pending
exhibit1012biontech026.jpg	Edgar Link	pending
exhibit1012biontech027.jpg	Edgar Link	pending
exhibit1012biontech028.jpg	Edgar Link	pending
exhibit1012biontech029.jpg	Edgar Link	pending
exhibit1012biontech030.jpg	Edgar Link	pending
exhibit1012biontech031.jpg	Edgar Link	pending
exhibit1012biontech032.jpg	Edgar Link	pending
exhibit1012biontech033.jpg	Edgar Link	pending
exhibit1012biontech034.jpg	Edgar Link	pending
exhibit1012biontech035.jpg	Edgar Link	pending
exhibit1012biontech036.jpg	Edgar Link	pending
exhibit1012biontech037.jpg	Edgar Link	pending
exhibit1012biontech038.jpg	Edgar Link	pending
exhibit1012biontech039.jpg	Edgar Link	pending
exhibit1012biontech040.jpg	Edgar Link	pending
autl-20231231_lab.xml	Edgar Link	unprocessable
autl-20231231_pre.xml	Edgar Link	unprocessable
autl-20231231_htm.xml	Edgar Link	completed
exhibit1012biontech041.jpg	Edgar Link	pending
exhibit1012biontech042.jpg	Edgar Link	pending
exhibit1012biontech043.jpg	Edgar Link	pending
exhibit1012biontech044.jpg	Edgar Link	pending
exhibit1012biontech045.jpg	Edgar Link	pending
exhibit1012biontech046.jpg	Edgar Link	pending
exhibit1012biontech047.jpg	Edgar Link	pending
exhibit1012biontech048.jpg	Edgar Link	pending
exhibit1012biontech049.jpg	Edgar Link	pending
exhibit1012biontech050.jpg	Edgar Link	pending
exhibit1012biontech051.jpg	Edgar Link	pending
exhibit1012biontech052.jpg	Edgar Link	pending
exhibit1012biontech053.jpg	Edgar Link	pending
exhibit1012biontech054.jpg	Edgar Link	pending
exhibit1012biontech055.jpg	Edgar Link	pending
exhibit1012biontech056.jpg	Edgar Link	pending
exhibit1012biontech057.jpg	Edgar Link	pending
exhibit1012biontech058.jpg	Edgar Link	pending
exhibit1012biontech059.jpg	Edgar Link	pending
exhibit1012biontech060.jpg	Edgar Link	pending
exhibit1012biontech061.jpg	Edgar Link	pending
exhibit1012biontech062.jpg	Edgar Link	pending
exhibit1012biontech063.jpg	Edgar Link	pending
exhibit1012biontech064.jpg	Edgar Link	pending
exhibit1012biontech065.jpg	Edgar Link	pending
exhibit1012biontech066.jpg	Edgar Link	pending
exhibit1012biontech067.jpg	Edgar Link	pending
exhibit1012biontech068.jpg	Edgar Link	pending
exhibit1012biontech069.jpg	Edgar Link	pending
exhibit1012biontech070.jpg	Edgar Link	pending
exhibit1012biontech071.jpg	Edgar Link	pending
exhibit1012biontech072.jpg	Edgar Link	pending
exhibit1012biontech073.jpg	Edgar Link	pending
exhibit1012biontech074.jpg	Edgar Link	pending
exhibit1012biontech075.jpg	Edgar Link	pending
exhibit1012biontech076.jpg	Edgar Link	pending
exhibit1012biontech077.jpg	Edgar Link	pending
exhibit1012biontech078.jpg	Edgar Link	pending
exhibit1012biontech079.jpg	Edgar Link	pending
exhibit1012biontech080.jpg	Edgar Link	pending
exhibit1012biontech081.jpg	Edgar Link	pending
exhibit1012biontech082.jpg	Edgar Link	pending
exhibit1012biontech083.jpg	Edgar Link	pending
exhibit1012biontech084.jpg	Edgar Link	pending
exhibit1012biontech085.jpg	Edgar Link	pending
exhibit1012biontech086.jpg	Edgar Link	pending
exhibit1012biontech087.jpg	Edgar Link	pending
exhibit1012biontech088.jpg	Edgar Link	pending
exhibit1012biontech089.jpg	Edgar Link	pending
exhibit1012biontech090.jpg	Edgar Link	pending
exhibit211-subsidiaries.htm	Edgar Link	pending
exhibit231consentofernstyo.htm	Edgar Link	pending
exhibit311-section302certi.htm	Edgar Link	pending
exhibit312-section302certi.htm	Edgar Link	pending
exhibit321-section906certi.htm	Edgar Link	pending
exhibit971-clawback.htm	Edgar Link	pending
exhibit971-clawback001.jpg	Edgar Link	pending
exhibit971-clawback002.jpg	Edgar Link	pending
exhibit971-clawback003.jpg	Edgar Link	pending
exhibit971-clawback004.jpg	Edgar Link	pending
exhibit971-clawback005.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
autl-20231231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUTL
Autolus Therapeutics plc Stock $autl

2024 Q1 Form 10-K Financial Statement

#000173046324000048 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUTL Autolus Therapeutics plc Stock $autl

2024 Q1 Form 10-K Financial Statement

#000173046324000048 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUTL
Autolus Therapeutics plc Stock $autl